pocketful logo
undefined logo

NSE: undefined BSE: undefined

₹-

(-%)

Mon, 16 Feb 2026, 03:38 am

mtf coin illustrationMTF 5x

Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    13170.55

  • Net Profit

    541.09

  • P/B

    5.78

  • Sector P/E

    31.55

  • P/E

    28.38

  • EV/EBITDA

    19.69

  • Debt/Equity (Industry)

    0.25

  • Interest Cover (Industry)

    12.50

  • ROCE (Industry)

    15.30

  • RONW (Industry)

    13.47

  • ROE

    22.86

  • ROCE

    26.03

  • Debt/Equity

    0

  • EPS (TTM)

    80.74

  • Dividend Yield

    0.35

  • Book Value

    415.64

  • Interest Cover

    1110.48

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (13x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (10.6x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Cash flow for Caplin Point Laboratories is expected to increase by more than 50% in 2 years time.
thumbs up icon

Cons

  • Caplin Point Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Caplin Point Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Caplin Point Laboratories's earnings are expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
  • Caplin Point Laboratories's earnings growth is positive but not above the India market average.
  • Caplin Point Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters70.5770.5770.5670.5670.56
FII6.566.486.145.704.86
DII2.052.102.222.012.11
Public20.8220.8521.0821.7322.47
Government00000

Read More

Technical Analysis

RSI

40.54

MACD

-24.45

50 DMA

1841.38

200 DMA

2007.36

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2170.301971.301872.601772.301673.601573.301374.30
Fibonacci1971.301895.281848.321772.301696.281649.321573.30
Camarilla1828.631810.381792.141772.301755.661737.421719.18

Pivots Level: Classic

R3

+398.00

2170.30

R2

+199

1971.30

R1

+100.30

1872.60

1772.30
1772.30
Pivot Point
LTP: 1730.10

S1

-98.70

1673.60

S2

-199

1573.30

S3

-398

1374.30

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1764.75

  • 20-EMA

    1784.07

  • 30-EMA

    1800.72

  • 50-EMA

    1833.76

  • 100-EMA

    1898.24

  • 200-EMA

    1945.07

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
05 Feb 2026board-meetingsQuarterly Results
05 Nov 2025board-meetingsQuarterly Results
07 Aug 2025dividend₹3.00 Dividend /Share12 Sept 2025
07 Aug 2025agm
15 May 2025dividend₹3.00 Dividend /Share30 May 2025
07 Aug 2024dividend₹2.50 Dividend /Share23 Sept 2024
07 Aug 2024agm
16 May 2024dividend₹2.50 Dividend /Share31 May 2024
07 Aug 2023dividend₹2.50 Dividend /Share14 Sept 2023
07 Aug 2023agm

Read More

Peer Comparison

Caplin Point Laboratories Ltd logo

Caplin Point Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

About

Caplin Point Laboratories manufactures wide range of ointments, creams and other external application preparations in addition to the regular segments of pharmaceutical formulations.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1990

Headquarters

CEO

C C Paarthipan

Employees

Contact

Website icon

Website

http://www.caplinpoint.net

Email icon

Email

investor@caplinpoint.net; info@caplinpoint.net

Phone icon

Phone

91-44-24968000/71148000/28156653

Location icon

Location

Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat, Chennai, Tamil Nadu, 600096

Read More

Company History

YearHistory
2018
  • USFDA completed inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu
2019
  • Caplin Point Laboratories partnered with Baxter Corporation for injectable portfolio
  • USFDA completed inspection at Caplin Steriles Injectable site
  • Caplin Steriles received USFDA nod for hemorrhage prevention drug
  • Caplin Point Labs received an EIR from USFDA for injectable facility
2020
  • Caplin Point Laboratories partnered with Xellia for injectable products
  • Caplin Point Laboratories received final approval from the US drug regulator for its Abbreviated New Drug Application for Phenylephrine Hydrochloride injection
  • Caplin Steriles received USFDA approval for Verapamil Hydrochloride Injection USP
2021
  • Caplin Point arm inked a strategic partnership with Canada's JAMP Pharma Group
  • Caplin Point Laboratories arm received USFDA nod for Neostigmine Methylsulfate Injection
2023
  • Caplin Point Laboratories received the Lifetime Achievement Award 2023
  • Caplin Point Laboratories received the Forbes Asia Best Under Billion Award 2023

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPBuy3963551899.626 Aug 2024
GRAVITON RESEARCH CAPITAL LLPSell3963551901.2826 Aug 2024
GRAVITON RESEARCH CAPITAL LLPBuy4444781761.7219 Aug 2024
GRAVITON RESEARCH CAPITAL LLPSell4444781763.5819 Aug 2024

Read More

News

Caplin Point Labs Q3 Net Profit Rises 17% YoY

Caplin Point Laboratories reported consolidated net profit of ₹1.64 billion for Q3, marking a 17.14% increase from ₹1.40 billion in the same quarter last year, demonstrating strong financial performance.

05 Feb 2026

co actions results

Caplin Point Labs Appoints Four New Directors

Caplin Point Laboratories shareholders approved appointment of four new directors through postal ballot on January 31, 2026, including two Vice-Chairmen and two Independent Directors.

03 Feb 2026

stocks

Caplin Point Labs Q3FY26 Earnings Call on Feb 5

Caplin Point Laboratories announces post-results conference call scheduled for February 05, 2026 at 16:00 hrs IST to discuss Q3FY26 financial performance for quarter ended December 31, 2025.

29 Jan 2026

co actions results

Caplin Steriles Gets USFDA Approval for Injectable

Caplin Steriles Limited receives final USFDA approval for Methylprednisolone Acetate Injectable Suspension, targeting a $57.4 million US market opportunity.

27 Jan 2026

stocks

Caplin Point Labs Reports Strong H1 FY26 Growth

Caplin Point Laboratories delivered robust H1 FY26 performance with 10.8% revenue growth to ₹1,044 crores and 21.6% PAT growth to ₹311 crores, maintaining strong margins and debt-free operations.

13 Jan 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800